Please login to the form below

Not currently logged in
Email:
Password:

Mersana appoints Anna Protopapas as president and CEO

Joins from Millenium Pharmaceuticals

Anna ProtopapasMersana Therapeutics has named Anna Protopapas as president and CEO.

Protopapas joins the firm, which engineers antibody-drug conjugates (ADCs), from Takeda subsidiary Millennium Pharmaceuticals, where she held the same role.

Commenting on her new role, Protopapas said: “ADCs are a proven approach to cancer with two drugs on the market and over 30 in the clinic. Mersana's Fleximer-ADCs are a best-in-class approach, which overcomes the limitations of other ADC technologies.

“I am very encouraged by the results to date and look forward to working alongside the team at Mersana to translate the technology into important therapies for patients.”

Protopapas has expansive strategic leadership experience, with a demonstrated track record in the biopharma industry. Amongst her time in the sector, Protopapas has served as a member of the executive committee of Takeda, led Takeda's oncology business during her time at Millennium Pharmaceuticals and also held the role of executive VP of global business development.

Protopapas will additionally join Mersana's board of directors.

4th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics